Simultaneous TCR and IL-2 agonism selectively enhances epitope-specific CD8 T-cell responses during chronic viral infection
Journal of Virology · 21.07.2026 · 100 (7)
DOI: 10.1128/jvi.00593-26 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Virology, erschienen am 21.07.2026. Verfasst von Masao Hashimoto und 10 weiteren Autor:innen. Beteiligte Einrichtung: Emory Vaccine Center, Emory University School of Medicine, Atlanta, Georgia, USA. Hauptthemen laut MEDLINE: CD8-Positive T-Lymphocytes, Interleukin-2, Lymphocytic Choriomeningitis, Receptors, Antigen, T-Cell. Die Arbeit nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Cue Biopharma, NIH HHS, NIAID NIH HHS.
Abstract (Originalsprache)
Interleukin-2 (IL-2) remains an attractive cytokine for enhancing antigen-specific CD8 T-cell responses in cancer immunotherapy, but systemic toxicity hinders its broad clinical application. To address this, various IL-2-based therapeutics have been engineered with altered IL-2 receptor bias or targeted delivery to tumors, the tumor microenvironment, or immune cell populations. Ideally, IL-2 signals should be selectively delivered to antigen-specific CD8 T cells, boosting their responses and promoting effector differentiation while sparing non-targeted populations. Immuno-STAT (Selective Targeting and Alteration of T cells) is a fusion protein platform comprising a bivalent peptide-major histocompatibility complex (MHC) class I complex and an affinity-attenuated IL-2 mutein that co-stimulates T-cell receptor and IL-2 signaling in epitope-specific CD8 T cells. Here, we investigated whether a D b GP 33-41 -targeted Immuno-STAT enhances D b GP33-specific CD8 T-cell responses in a mouse model of chronic lymphocytic choriomeningitis virus infection. Immuno-STAT treatment selectively expanded D b GP33-specific CD8 T cells with an effector-like phenotype. Non-targeted D b GP276-specific CD8 T cells showed little to no expansion in response to D b GP 33-41 -targeted Immuno-STAT therapy, underscoring the selectivity of this approach. However, minor changes in phenotypic markers, including increased expression of CD25 and CX3CR1, were observed in non-targeted CD8 T cells, likely reflecting bystander IL-2 signaling. Combining Immuno-STAT with PD-1 blockade augmented D b GP33-specific CD8 T-cell responses more effectively than PD-1 blockade alone, with minor effects on the non-targeted D b GP276-specific population. These findings inform the clinical development of Immuno-STAT and other IL-2 therapeutics and highlight the value of coordinated TCR and IL-2 stimulation during chronic antigen exposure, alone or in combination with PD-1 blockade. IMPORTANCE Interleukin-2 (IL-2) is a key cytokine for promoting effector differentiation of antigen-specific CD8 T cells and remains an attractive agent in cancer immunotherapy, but systemic toxicity limits its clinical use. This study addresses a central challenge in IL-2-based immunotherapy: delivering IL-2 to cognate antigen-specific CD8 T cells while minimizing activation of non-targeted populations. Using a mouse model of chronic lymphocytic choriomeningitis virus (LCMV) infection, we show that the Immuno-STAT (Selective Targeting and Alteration of T cells) platform selectively expands targeted virus-specific CD8 T cells and enhances their function while limiting effects on non-targeted populations. We also show that combining Immuno-STAT with PD-1 blockade further enhances targeted virus-specific CD8 T-cell responses during chronic LCMV infection. These findings provide mechanistic and preclinical support for integrating T-cell receptor specificity with IL-2 signaling to advance cancer immunotherapy and guide next-generation IL-2 therapeutics for cancer and chronic infection.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Emory Vaccine Center, Emory University School of Medicine, Atlanta, Georgia, USA.
- Department of Microbiology and Immunology, Emory University School of Medicine, Atlanta, Georgia, USA.
- Immunology Laboratory, Department of Biomedical Engineering, Indian Institute of Technology Ropar, Rupnagar, India.
- Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.
- Department of Medicine, Harvard Medical School, Boston, Massachusetts, USA.
- Cue Biopharma, Boston, Massachusetts, USA.
ORCID-Profile: Masao Hashimoto, Mohammad Affan Khan, Gordon J Freeman, Rafi Ahmed
Förderung
- Cue Biopharma
- NIH HHS
- NIAID NIH HHS
- National Institutes of Health
Zitieren
APA
Hashimoto, M., Khan, M. A., Akhtar, A., Agrewala, J. N., Freeman, G. J., Girgis, N., Zhang, Y., Low, S., Quayle, S. N., Suri, A., & Ahmed, R. (2026). Simultaneous TCR and IL-2 agonism selectively enhances epitope-specific CD8 T-cell responses during chronic viral infection. Journal of Virology, 100(7). https://doi.org/10.1128/jvi.00593-26
Vancouver
Hashimoto M, Khan MA, Akhtar A, Agrewala JN, Freeman GJ, Girgis N, et al. Simultaneous TCR and IL-2 agonism selectively enhances epitope-specific CD8 T-cell responses during chronic viral infection. Journal of Virology. 2026;100(7). doi:10.1128/jvi.00593-26
BibTeX
@article{Hashimoto2026,
author = {Hashimoto, Masao and Khan, Mohammad Affan and Akhtar, Akil and Agrewala, Javed N and Freeman, Gordon J and Girgis, Natasha and Zhang, Yu and Low, Simon and Quayle, Steven N and Suri, Anish and Ahmed, Rafi},
title = {Simultaneous TCR and IL-2 agonism selectively enhances epitope-specific CD8 T-cell responses during chronic viral infection},
journal = {Journal of Virology},
year = {2026},
volume = {100},
number = {7},
doi = {10.1128/jvi.00593-26}
}
EUVIMED